NDA 220910 · Revolution Medicines
Rasonque
Daraxonrasib · Oral
NovelPriority reviewOrphanCDER novel approval, Aug 26, 2026: To treat metastatic pancreatic cancer
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 26, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
15
5 Phase 3, 10 recruiting
FAERS reports
10
10 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2026.
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. RASONQUE is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. ( 1 )
Mechanism: Daraxonrasib is an inhibitor of the RAS GTPase family. Daraxonrasib binds to cyclophilin A, resulting in a binary complex that binds to the active, GTP-bound state of RAS. The tri-complex inhibits RAS signaling by blocking interactions with downstream effectors and promoting GTP hydrolysis to the inactive GDP-bound state of RAS. Daraxonrasib inhibition of wild-type and mutant variants of KRAS, NRAS, and HRAS induces tumor growth suppression and apoptosis. In RAS-dependent models of pancreatic adenocarcinoma, daraxonrasib treatment led to tumor growth inhibition and regression and is...
Therapeutic areas: Oncology · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 26, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelMedication Guide
2 products under this application
- RASONQUE · DARAXONRASIB 100MG · TABLET, ORAL · Prescription
- RASONQUE · DARAXONRASIB 150MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Daraxonrasib" as an intervention, any sponsor and status, largest first.
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07491445 · 900 participants (planned) · Start Mar 9, 2026 · Primary completion Apr 2028
Drug: daraxonrasib; gemcitabine and 1 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 106 sites in all
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT06881784 · 590 participants (planned) · Start May 6, 2025 · Primary completion Dec 1, 2027
Drug: daraxonrasib; docetaxel · For: NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Long Beach, California · 199 sites in all
Revolution Medicines, Inc.Industry
NCT07349537 · 574 participants (planned) · Start Jan 8, 2026 · Primary completion Apr 2028
Drug: RMC-5127; daraxonrasib and 1 more · For: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Adenocarcinoma and 7 more
Sites: New Haven, Connecticut; Baltimore, Maryland; Boston, Massachusetts · 9 sites in all
Revolution Medicines, Inc.Industry
NCT06128551 · 534 participants (planned) · Start Nov 14, 2023 · Primary completion Dec 2028
Drug: Elironrasib; Daraxonrasib · For: Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma
Sites: Duarte, California; Orange, California; Sacramento, California · 56 sites in all
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07252232 · 500 participants (planned) · Start Dec 15, 2025 · Primary completion May 10, 2029
Drug: daraxonrasib · For: Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 86 sites in all
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pivotal-lookingActive, not recruiting
Revolution Medicines, Inc.Industry
NCT06625320 · 500 participants · Start Oct 16, 2024 · Primary completion Jun 2026
Drug: RMC-6236; Gemcitabine and 6 more · For: Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma
Sites: Gilbert, Arizona; Phoenix, Arizona; Duarte, California · 60 sites in all
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07805954 · 400 participants (planned) · Start Aug 28, 2026 · Primary completion Mar 2029
Drug: daraxonrasib; gemcitabine and 2 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Jacksonville, Florida · 6 sites in all
Revolution Medicines, Inc.Industry
NCT07397338 · 370 participants (planned) · Start Jan 30, 2026 · Primary completion May 2029
Drug: Daraxonrasib; Elironrasib and 6 more · For: Advanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC) and 3 more
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dehydration4
- diarrhoea4
- nausea4
- vomiting4
- rash2
- stomatitis2
- abdominal pain upper1
- ageusia1
- blood potassium abnormal1
- blood pressure decreased1
- cardiac disorder1
- disease progression1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.
Wolpin BM, Park W, Garrido-Laguna I, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Multicenter Study
- Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
O'Reilly EM, Wainberg ZA, Hendifar AE, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Arbour KC, Punekar S, Luo J, et al. · N Engl J Med 2026 · Multicenter Study, Clinical Trial, Phase I
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.
Aronchik I, Kar S, Zhuang Y, et al. · Nat Med 2026 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: Revolution Medicines
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.